US Patent

US9433679 — Use of TRMP8 for treating opthalmic diseases or conditions involving tearing

Method of Use · Assigned to Consejo Superior de Investigaciones Cientificas CSIC · Expires 2031-09-08 · 5y remaining

Vulnerability score 64/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects the use of TRMP8 receptor agonist and antagonist ligands for treating dry eye and epiphora.

USPTO Abstract

The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist.

Drugs covered by this patent

Tryptyr (ACOLTREMON) · Alcon Labs Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1900`	—	Tryptyr

Patent Metadata

Patent number: US9433679
Jurisdiction: US
Classification: Method of Use
Expires: 2031-09-08
Drug substance claim: No
Drug product claim: No
Assignee: Consejo Superior de Investigaciones Cientificas CSIC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.